CureMS

#multiplesclerosis #transplant

CyTOF - Wikipedia

🔵 Two studies used CyTOF to map immune reconstitution post-AHSCT in MS: Gavasso et al. found CD4⁺ memory T cell loss and naïve B cell expansion; Müller et al. reported Th1/Th17, MAIT cell decline, and relapse link to IgD⁺IgM⁺ B cells.
🟢 More info: curems.net/benefits-of-...

The ECTRIMS/EBMT consensus (www.nature.com/articles/s41...) states AHSCT should be offered to RRMS patients unresponsive to HE-DMTs. Neurologists and patients must weigh AHSCT’s unique long-term benefits—over 50% achieve NEDA-3 for 10+ years without further therapy. See curems.net/benefits-of-...

CureMS.net screened PubMed and Google Scholar, reviewing 21 studies on RRMS patients treated with AHSCT (intermediate conditioning, 1–10 years follow-up). At 10 years, 40–78% maintained NEDA-3; BEAM+ATG studies reported 55–78%. Total patients: 1145 (possible duplicates). curems.net/benefits-of-...

CureMS.net A GUIDE ON AHSCT FOR MS No miracle claims, just scientific facts. A light at the end of the tunnel. Is it possible to cure MS? No miracle claims, just scientific facts. A light at the end of the tunn...

Although AHSCT (autologous hematopoietic stem cell transplantation) is a treatment option for some pwMS, this option is not always communicated to them.
Here are some personal reflections on the doctor-patient relationship.
More info at curems.net
Read the new section here lnkd.in/dyhgnUqP

Welcome to curems.net, an Evidence-based, nonprofit resource on Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for MS. 
🟢 Free, updated, downloadable materials on transplant.
🟢 Providing reliable information to guide patients and healthcare professionals.  
📌 Visit curems.net